.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,004,929

« Back to Dashboard

Details for Patent: 6,004,929

Title: Biologically active PDGF A-chain homodimers
Abstract:Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the A-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the A-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the A-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s): Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Filing Date:Mar 29, 1995
Application Number:08/412,551
Claims:1. A substantially pure protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity and being essentially free of the B-chain of PDGF.

2. A protein homodimer according to claim 1 wherein said polypeptide chains consist of residues 1 to 104 of PDGF A-chain as shown in FIG. 9.

3. The protein homodimer of claim 1 wherein each of said chains comprise residues 9-95 of PDGF A-chain as shown in FIG. 9.

4. A substantially pure protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity.

5. A therapeutic composition comprising a protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity and being essentially free of the B-chain of PDGF, and a physiologically acceptable carrier or diluent.

6. A therapeutic composition according to claim 5 wherein said polypeptide chains consist of residues 1 to 104 of PDGF A-chain as shown in FIG. 9.

7. The therapeutic composition of claim 5 wherein each of said chains comprise residues 9-95 of PDGF A-chain as shown in FIG. 9.

8. A therapeutic composition comprising a protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity, and a physiologically acceptable carrier or diluent.

9. The therapeutic composition of claim 5 or 8, including an adjuvant.

10. The therapeutic composition of claim 9 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.

11. The therapeutic composition of claim 5 or 8 wherein said protein is present in a concentration of from about 1 to 50 ug/ml of total volume.

12. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a substantially pure protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity and being essentially free of the B-chain of PDGF, and a physiologically acceptable carrier or diluent.

13. A method according to claim 12 wherein said polypeptide chains consist of residues 1 to 104 of PDGF A-chain as shown in FIG. 9.

14. The method of claim 12, wherein said method further comprises administering an adjuvant in combination with said protein homodimer.

15. The method of claim 14 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.

16. The method of claim 12 wherein the concentration of said protein in said diluent is from about 1 to 50 .mu.g/ml of total volume.

17. The method of claim 12 wherein each of said chains comprise residues 9-95 of PDGF A-chain as shown in FIG. 9.

18. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a substantially pure protein homodimer having two polypeptide chains, each of said chains consisting of from 87-104 amino acid residues and comprising residues 23-95 of PDGF A-chain as shown in FIG. 9, said protein exhibiting mitogenic activity, and a physiologically acceptable carrier or diluent.

19. A protein homodimer consisting of human PDGF A-chains as shown in FIG. 9 from residue 1 to residue 104, said protein being essentially free of other proteins of mammalian or viral origin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc